Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6311586 | 0.82 | KDM1A (0.47) | FUCA1ACHEKDM1ADRD2DRD3 | |
| SCHEMBL1711734 | 0.80 | FUCA1 (0.49) | FUCA1SIGMAR1 | |
| SCHEMBL6325478 | 0.80 | KDM1A (0.50) | FUCA1ACHEKDM1ADRD2DRD3 | |
| SCHEMBL5811952 | 0.80 | DRD2 (0.42) | FUCA1KDM1ADRD2DRD3CXCR3 | |
| SCHEMBL25391591 | 0.79 | FUCA1 (0.45) | FUCA1ACHEKDM1ADRD2DRD3 | |
| SCHEMBL20471517 | 0.79 | FUCA1 (0.45) | FUCA1ACHEKDM1ADRD2DRD3 | |
| Hydrochloric Acid SCHEMBL22076642 | 0.78 | FUCA1 (0.44) | FUCA1ACHEKDM1ADRD2DRD3 | |
| SCHEMBL6317794 | 0.77 | FUCA1 (0.51) | FUCA1SIGMAR1 | |
| SCHEMBL1008411 | 0.77 | FUCA1 (0.51) | FUCA1SIGMAR1 | |
| SCHEMBL27029864 | 0.77 | FUCA1 (0.45) | FUCA1ACHEKDM1ADRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004113-A1 | New bispidine compounds useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2005-01-06 | — | — | US | disclosed |
| EP-1192156-B1 | BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2004-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004113-A1 | New bispidine compounds useful in the treatment of cardiac arrhythmias | DRD2, ADRA1D, KCND2 | FUCA1 4764/4885ACHE 737/4885KDM1A 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.